Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis

Blood (2025) 146 (Supplement 1): 3623.

https://doi.org/10.1182/blood-2025-3623

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Daniel Wiseman, Jak Laight, Rebecca Boucher, Chhaya Sankhalpara, Rebecca Record, Jennifer Byrne, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Srinivasan Narayanan, Rob Sellar, Kiran Batta, Manoj Raghavan, Dr. Emma Searle, Catherine Cargo, Steve Knapper, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 488.

https://doi.org/10.1182/blood-2025-488

Published: 2025

Journal Articles

Patient experience sub-study of a randomised UK multicentre Phase 2 trial of ASTX727 versus hydroxycarbamide/best supportive care in myelodysplastic (MDS)/myeloproliferative (MPN) overlap syndromes (AMMO)

Ashleigh Ward, Sally Taylor, Grant Punnett, Ramsay Devaraj, Chhaya Sankhalpara, Rebecca Record, Kiran Batta, Jennifer Byrne, Catherine Cargo, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Steve Knapper, Austin Kulasekararaj, Srinivasan Narayanan, Manoj Raghavan, Rob Sellar, Daniel Wiseman, Janelle Yorke

Blood (2025) 146 (Supplement 1): 8164.

https://doi.org/10.1182/blood-2025-8164

Published: 2025

Journal Articles

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

Blood (2025) 146 (15): 1862–1867.

https://doi.org/10.1182/blood.2025029556

Published: 2025

Includes: Supplemental data

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project

Fabio Efficace, Karin A Koinig, Francesco Cottone, David Bowen, Moshe Mittelman, Saskia M. C. Langemeijer, Dominic Culligan, Kalman Filanovsky, Gregory A. Abel, Michael Storck, Alexandra Smith, Corine Van Marrewijk, Martin Dugas, Theo M de Witte, Reinhard Stauder

Blood (2021) 138 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2021-147176

Published: 2021

Journal Articles

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Blood (2021) 138 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2021-146061

Published: 2021

Journal Articles

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Blood (2018) 132 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2018-99-111838

Published: 2018

Journal Articles

Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study

Blood (2018) 132 (Supplement 1): 3097.

https://doi.org/10.1182/blood-2018-99-112508

Published: 2018

Journal Articles

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Blood (2018) 132 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2018-99-115928

Published: 2018

Journal Articles

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 425.

https://doi.org/10.1182/blood.V130.Suppl_1.425.425

Published: 2017

Journal Articles

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

Blood (2017) 130 (Supplement 1): 1690.

https://doi.org/10.1182/blood.V130.Suppl_1.1690.1690

Published: 2017

Journal Articles

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 158.

https://doi.org/10.1182/blood.V130.Suppl_1.158.158

Published: 2017

Journal Articles

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, David Bowen, MD PhD, Jaroslav Cermak, MD PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin Huls, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic Culligan, Marta Krejci, Corine van Marrewijk, Jackie Droste, PhD, Alexandra Smith, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2015) 126 (23): 2865.

https://doi.org/10.1182/blood.V126.23.2865.2865

Published: 2015

Journal Articles

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Alan K. Burnett, MD, David Bowen, MD, PhD, Nigel Russell, MD, Steven Knapper, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Asim Khwaja, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Dominic Culligan, Helen Clark, Robert K. Hills, MA, MSc, DPhil

Blood (2013) 122 (21): 622.

https://doi.org/10.1182/blood.V122.21.622.622

Published: 2013

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

John Radford, Sally Barrington, Nicholas Counsell, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Stewart Coltart, Dominic Culligan, Andrew Lister, Eric Bessell, Anton Kruger, Bilyana Popova, Barry Hancock, Peter Hoskin, Timothy Illidge, Michael O'Doherty

Blood (2012) 120 (21): 547.

https://doi.org/10.1182/blood.V120.21.547.547

Published: 2012

Journal Articles

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Stephen J. Proctor, Jennifer Wilkinson, Gail Jones, Gillian C. Watson, Helen H. Lucraft, Tryfonia Mainou-Fowler, Dominic Culligan, Michael J. Galloway, Katrina M. Wood, Richard J. Q. McNally, Peter W. James, John R. Goodlad

Blood (2012) 119 (25): 6005–6015.

https://doi.org/10.1182/blood-2011-12-396556

Published: 2012

Includes: Supplemental data

Journal Articles

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Michal Sieniawski, Jennifer Wilkinson, Dominic Culligan, John Davies, John Goodlad, Ruth Jarrett, Anne L Lennard, Helen Lucraft, Tryfonia Mainou-Fowler, Pam McKay, Fiona Scott, Sudhir Tauro, Jo White, Stephen J Proctor

Blood (2008) 112 (11): 2604.

https://doi.org/10.1182/blood.V112.11.2604.2604

Published: 2008

Journal Articles

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

John Radford, Michael O’Doherty, Sally Barrington, Wendi Qian, Philippa Patrick, Stewart Coltart, Dominic Culligan, Jennie Wimperis, Eric Bessell, David Linch, Peter Johnson, David Cunningham, T. Andrew Lister, Peter Hoskin, Ruth Pettengell, Barry Hancock, Timothy Illidge

Blood (2008) 112 (11): 369.

https://doi.org/10.1182/blood.V112.11.369.369

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Patient experience sub-study of a randomised UK multicentre Phase 2 trial of ASTX727 versus hydroxycarbamide/best supportive care in myelodysplastic (MDS)/myeloproliferative (MPN) overlap syndromes (AMMO)

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry

A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only